The Comparison of 24 and 48 Hours Culture on In vitro Maturation of Oocyte using Menstrual Blood Stem Cells Secretome in Polycystic Ovary
Subject Areas : Journal of Animal BiologyHilda Rastegari 1 , نسیم حیاتی رودباری 2 , Somaieh Kazemnejad 3 , Soheila Ansaripour 4
1 - Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iranehran, Iran
2 - Department of Biology, Science and Research Branch, Islamic Azad University, Tehran, Iran
3 - Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
4 - Reproductive Biotechnology Research Center, Avicenna Research Institute, ACECR, Tehran, Iran
Keywords: Secretome, Menstrual blood stem cells, IVM, Melatonin, Follicular fluids, PCOS,
Abstract :
The application of mesenchymal stem cells is a novel approach in regenerative medicine and infertility. Recently, culture enrichment using the secretome obtained from these cells, as well as the optimal time for culture, have been considered in order to improve the results of in vitro maturation (IVM), especially in women with polycystic ovaries (PCOS). The purpose of this study is comparing 24 and 48 timing on IVM using secretome of menstrual blood stem cells (MenSCs) along with follicular fluid and melatonin in PCOS women. 400 germinal vesicle oocytes were collected from 100 PCOS patients, as the best candidates for IVM, and randomly divided into four groups: control, secretome, follicular fluid and melatonin. Oocyte maturation was evaluated at 24 and 48 hours. Also, the effect patient’s age on the results of the study was evaluated in the age groups under 30 and over 30 years old in both time periods. Oocyte maturation rate showed a significant increase in 24 hours in the group enriched with secretome compared to the control (p < 0.05). Also, matured oocytes were noticeably higher in melatonin enriched group, in 48 hours, compared to the control (p < 0.001). Moreover, according to our findings, the age of the women did not have a significant effect on the oocyte maturation rate in the 24-hour culture, while in the younger age group, the oocyte maturation rate increased significantly both in secretome and melatonin groups compared to the control group. As a result, the culture time of 24 hours with IVM medium enriched by secretome is the optimal time in order to increase oocyte maturation in PCOS women. Also, the use of melatonin seems to be an effective strategy to improve egg maturation in extended culture times.
1. Akbari H., Eftekhar Vaghefi S.H., Shahedi A., Habibzadeh V., Mirshekari T. R., Ganjizadegan A., Mollaei H., Ahmadi M., Nematollahi-Mahani S.N. 2017. Mesenchymal stem cell-conditioned medium modulates apoptotic and stress-related gene expression, ameliorates maturation and allows for the development of immature human oocytes after artificial activation. Genes, 8(12):371.
2. Akbari H., Vaghefi S.H.E., Shahedi A., Habibzadeh V., Mirshekari T.R., Shekari M.A., Nejatbakhsh R. 2018. Conditioned mediums and human oocytes in vitro maturation. International Journal of Pharmaceutical and Phytopharmacological Research (eIJPPR), 8(2):64-71.
3. Chen L., Qu J., Xiang C. 2019. The multi-functional roles of menstrual blood-derived stem cells in regenerative medicine. Stem Cell Research and Therapy, 10(1):1-10.
4. Doroudi R., Changizi Z., Nematollahi-Mahani S.N. 2021. Effects of melatonin and human follicular fluid supplementation of in vitro maturation medium on mouse vitrified germinal vesicle oocytes: A laboratory study. International Journal of Reproductive BioMedicine, 19(10):889.
5. Fathi-Kazerooni M., Fattah-Ghazi S., Darzi M., Makarem J., Nasiri R., Salahshour F., Dehghan-Manshadi S.A., Kazemnejad S. 2022. Safety and efficacy study of allogeneic human menstrual blood stromal cells secretome to treat severe COVID-19 patients: clinical trial phase I & II. Stem Cell Research and Therapy, 13(1):96.
6. Haryadi D., Sadewa A.H., Mubarika S., Dasuki D. 2019. The potential application of conditioned media-mesenchymal stem cells on human oocyte maturation in assisted reproductive technology: a quasi-experimental based-study at Dr. Sardjito General Hospital, Yogyakarta, Indonesia. Bali Medical Journal, 8(3):741-748.
7. Heinzmann J., Mattern F., Aldag P., Bernal-Ulloa S.M., Schneider T., Haaf T., Niemann H. 2015. Extended in vitro maturation affects gene expression and DNA methylation in bovine oocytes. MHR: Basic Science of Reproductive Medicine, 21(10):770-782.
8. Jafarzadeh H., Nazarian H., Ghaffari Novin M., Shams Mofarahe Z., Eini F., Piryaei A. 2018. Improvement of oocyte in vitro maturation from mice with polycystic ovary syndrome by human mesenchymal stromal cell–conditioned media. Journal of Cellular Biochemistry, 119(12):10365-10375.
9. La X., Zhao J., Wang Z. 2019. Clinical Application of In Vitro Maturation of Oocytes. In Embryology-Theory and Practice: IntechOpen.
10. Li Y., Liu H., Wu K., Liu H., Huang T., Chen Z. J., Zhao S., Ma J., Zhao H. 2019. Melatonin promotes human oocyte maturation and early embryo development by enhancing clathrin‐mediated endocytosis. Journal of pineal research, 67(3):e12601.
11. Lin T., Lee J.E., Kang J.W., Oqani R.K., Cho E.S., Kim S.B., Il Jin D. 2018. Melatonin supplementation during prolonged in vitro maturation improves the quality and development of poor‐quality porcine oocytes via anti‐oxidative and anti‐apoptotic effects. Molecular Reproduction and Development, 85(8-9):665-681.
12. Lord T., Nixon B., Jones K.T., Aitken R.J. 2013. Melatonin prevents postovulatory oocyte aging in the mouse and extends the window for optimal fertilization in vitro. Biology of Reproduction, 88(3):67.
13. Lu C., Zhang Y., Zheng X., Song X., Yang R., Yan J., Feng H., Qiao J. 2018. Current perspectives on in vitro maturation and its effects on oocyte genetic and epigenetic profiles. Science China Life Sciences, 61:633-643.
14. Madkour A., Bouamoud N., Kaarouch I., Louanjli N., Saadani B., Assou S., Aboulmaouahib S., Sefrioui O., Amzazi S., Copin H. 2018. Follicular fluid and supernatant from cultured cumulus-granulosa cells improve in vitro maturation in patients with polycystic ovarian syndrome. Fertility and Sterility, 110(4): 710-719.
15. Miraki S., Mokarizadeh A., Banafshi O., Assadollahi V., Abdi M., Roshani D., Fathi F. 2017. Embryonic stem cell conditioned medium supports in vitro maturation of mouse oocytes. Avicenna Journal of Medical Biotechnology, 9(3):114.
16. Nikmard F., Hosseini E., Bakhtiyari M., Ashrafi M., Amidi F., Aflatoonian R. 2017. Effects of melatonin on oocyte maturation in PCOS mouse model. Animal Science Journal, 88(4):586-592.
17. Plancha C. E., Rodrigues P., Marques M., Almeida J. M., Navarro-Costa P. 2021. The time is ripe for oocyte in vitro maturation. Journal of Assisted Reproduction and Genetics, 38(6):1281-1283.
18. Shokri M.R., Bozorgmehr M., Ghanavatinejad A., Falak R., Aleahmad M., Kazemnejad S., Shokri F., Zarnani A-H. 2019. Human menstrual blood-derived stromal/stem cells modulate functional features of natural killer cells. Scientific Reports, 9(1):10007.
19. Vuong L.N., Le A.H., Ho V.N., Pham T. D., Sanchez F., Romero S., De Vos M., Ho T.M., Gilchrist R.B., Smitz J. 2020. Live births after oocyte in vitro maturation with a prematuration step in women with polycystic ovary syndrome. Journal of Assisted Reproduction and Genetics, 37:347-357.
20. Yang H., Kolben T., Meister S., Paul C., van Dorp J., Eren S., Kuhn C., Rahmeh M., Mahner S., Jeschke U., von Schönfeldt V. 2021. Factors Influencing the In Vitro Maturation (IVM) of Human Oocyte. Biomedicines, 9(12):1904.
21. Yang Q., Zhu L., Wang M., Huang B., Li Z., Hu J., Xi Q., Liu J., Jin L. 2021. Analysis of maturation dynamics and developmental competence of in vitro matured oocytes under time-lapse monitoring. Reproductive Biology and Endocrinology, 19(1):183.
22. Zafardoust S., Kazemnejad S., Darzi M., Fathi-Kazerooni M., Rastegari H., Mohammadzadeh A. 2020. Improvement of pregnancy rate and live birth rate in poor ovarian responders by Intraovarian Administration of autologous menstrual blood derived-Mesenchymal Stromal Cells: Phase I/II Clinical Trial. Stem Cell Reviews and Reports, 16:755-763.
